Data / Drug companies / Ucb, Inc.
Ucb, Inc.: 38 products in the FDA NDC directory, labeler code 50474
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Ucb, Inc. (labeler code 50474) lists 38 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 38 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on March 1, 2026.
The request: Watch Ucb, Inc. (FDA labeler code 50474): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 50474
- Products in commercial distribution
- 38
- Packages
- 58
- Finished drugs by generic name
- 9
- Prescription products
- 38
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 1, Schedule V 7
- Flagged as original packager
- 19 of 19 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- April 24, 2000
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 27 | 71.1% |
| Biologics (BLA) | 11 | 28.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 38 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Levetiracetam | 8 | 87 |
| Brivaracetam | 7 | 17 |
| Rotigotine | 7 | 1 |
| Bimekizumab | 4 | 1 |
| Rozanolixizumab | 4 | 1 |
| Zilucoplan | 3 | 1 |
| Certolizumab pegol | 3 | 1 |
| Midazolam | 1 | 6 |
| Doxecitine and doxribtimine | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 13 | 34.2% |
| Tablet, film coated | 9 | 23.7% |
| Patch, extended release | 6 | 15.8% |
| Kit | 2 | 5.3% |
| Tablet, film coated, extended release | 2 | 5.3% |
| Solution | 2 | 5.3% |
| Spray | 1 | 2.6% |
| Injection, solution, concentrate | 1 | 2.6% |
| Powder, for solution | 1 | 2.6% |
| Injection, suspension | 1 | 2.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Nonergot Dopamine Agonist | 6 |
| Neonatal Fc Receptor Blocker | 4 |
| Complement Inhibitor | 3 |
| Tumor Necrosis Factor Blocker | 2 |
| Benzodiazepine | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Kygevvi | 50474-350 | Powder, for solution | New drug applications (NDA) | March 1, 2026 |
| Cimzia | 50474-750 | Injection, solution | Biologics (BLA) | March 1, 2025 |
| Bimzelx | 50474-783 | Injection, solution | Biologics (BLA) | December 5, 2024 |
| Bimzelx | 50474-782 | Injection, solution | Biologics (BLA) | December 5, 2024 |
| Rystiggo | 50474-983 | Injection, solution | Biologics (BLA) | June 14, 2024 |
| Rystiggo | 50474-982 | Injection, solution | Biologics (BLA) | June 14, 2024 |
| Rystiggo | 50474-981 | Injection, solution | Biologics (BLA) | June 14, 2024 |
| Zilbrysq | 50474-992 | Injection, solution | New drug applications (NDA) | January 3, 2024 |
| Zilbrysq | 50474-991 | Injection, solution | New drug applications (NDA) | January 3, 2024 |
| Zilbrysq | 50474-990 | Injection, solution | New drug applications (NDA) | January 3, 2024 |
| Bimzelx | 50474-781 | Injection, solution | Biologics (BLA) | October 17, 2023 |
| Bimzelx | 50474-780 | Injection, solution | Biologics (BLA) | October 17, 2023 |
| Rystiggo | 50474-980 | Injection, solution | Biologics (BLA) | June 26, 2023 |
| Nayzilam | 50474-500 | Spray | New drug applications (NDA) | May 17, 2019 |
| Briviact | 50474-970 | Injection, suspension | New drug applications (NDA) | May 12, 2016 |
| Briviact | 50474-870 | Solution | New drug applications (NDA) | May 12, 2016 |
| Briviact | 50474-770 | Tablet, film coated | New drug applications (NDA) | May 12, 2016 |
| Briviact | 50474-670 | Tablet, film coated | New drug applications (NDA) | May 12, 2016 |
| Briviact | 50474-570 | Tablet, film coated | New drug applications (NDA) | May 12, 2016 |
| Briviact | 50474-470 | Tablet, film coated | New drug applications (NDA) | May 12, 2016 |
| Briviact | 50474-370 | Tablet, film coated | New drug applications (NDA) | May 12, 2016 |
| Neupro | 50474-808 | Kit | New drug applications (NDA) | April 2, 2012 |
| Neupro | 50474-806 | Patch, extended release | New drug applications (NDA) | April 2, 2012 |
| Neupro | 50474-805 | Patch, extended release | New drug applications (NDA) | April 2, 2012 |
| Neupro | 50474-804 | Patch, extended release | New drug applications (NDA) | April 2, 2012 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.